Clinical trials: Demyelinating Disorder
Multiple Sclerosis
A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
Primary Objective: To assess the pharmacokinetic (PK) parameters of teriflunomide after a single oral dose of 14 mg administration in Chinese healthy subjects Secondary Objective: To assess the safety and tolerability after a…
- Trial name
- NCT02046629
- Testing
- Teriflunomide HMR1726, cholestyramine
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
Accurate Diagnosis of Multiple Sclerosis Using PET/MR
Multiple sclerosis (MS) is an immune-mediated chronic inflammatory demyelinating disease of the central nervous system. Its main feature is progressive demyelination, which ultimately leads to axon damage and neuron loss.
- Trial name
- NCT04521439
- Testing
- 18F-florbetapir PET+MRSI
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), CMT (Charcot Marie Tooth Disease)
Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)
The main purpose of this study is to assess the clinical feasibility of diffusion tensor imaging (DTI) for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- PIDC (NCT03460951)
- Testing
- cervical MRI
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Sclerosis
Telerehabilitation Based Motor Imagery and Action Observation Training in Multiple Sclerosis
This study aims to investigate the effects of the treatment combination consisting of motor imagery and action observation therapy on balance, functional mobility, lower extremity muscle strength, fatigue and quality of life.
- Trial name
- NCT06295601
- Testing
- Traditional rehabilitation, Action observation therapy and motor imagery
- Where
- Turkey (Türkiye)
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Inonu University
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for treatment of acute optic neuritis and/or transverse…
- Trial name
- NCT01777412
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Guillain-Barre Syndrome, CIDP
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies…
- Conditions
- Guillain-Barre Syndrome, CIDP, Multifocal Motor Neuropathy
- Trial name
- NCT01655394
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Cologne
Multiple Sclerosis, Relapsing-Remitting
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
- Trial name
- P1A114347 (NCT01431937)
- Testing
- GSK2018682
- Where
- 3 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis
Multiple sclerosis (MS) affects 1 in 1000 people in western countries, mainly women in their childbearing years. It is an autoimmune disease of the central nervous system (CNS), which results in a chronic focal inflammatory…
- Trial name
- NCT00127075
- Testing
- nomegestrol acetate, estradiol
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Tay-Sachs Disease, Porphyria, Erythropoietic
Diagnostic and Screening Study of Genetic Disorders
OBJECTIVES: I. Determine the phenotypic heterogeneity of patients with genetic disorders including their clinical spectrum and natural history. II.
- Conditions
- Tay-Sachs Disease, Porphyria, Erythropoietic, Leukodystrophy, Globoid Cell, Metabolism, Inborn Errors
- Trial name
- NCT00006057
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Center for Research Resources (NCRR)
Multiple Sclerosis
Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years.
- Trial name
- EXCEED (NCT02523703)
- Testing
- glutamate and aspartate
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, Acute Optic Neuritis
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers.
- Trial name
- NCT02833142
- Testing
- BIIB033 (opicinumab)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt
The primary study aim is to depict the demographics, clinical and para clinical features of patients attending five tertiary referral multiple sclerosis (MS) centers in Egypt.
- Trial name
- NCT02970370
- Testing
- no intervention
- Volunteers
- 2,752 people
- Sponsor
- Cairo University
Multiple Sclerosis
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
This is a study aimed to characterize [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of [18F]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple…
- Trial name
- NCT01428505
- Testing
- [18F]PBR111
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Transcranial Electrical Stimulation for Treating Chronic Pain in Inflammatory Demyelinating Diseases
Non-invasive neurostimulation can effectively improve patients' symptoms and has shown good therapeutic efficacy in alleviating the symptoms of IIDDs (Inflammatory Immune-mediated Demyelinating Diseases).
- Trial name
- NCT06942611
- Testing
- transcranial electrical stimulation treatment.
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple Sclerosis, Constipation
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
The purpose of the study is to assess how safe and effective the drug Lubiprostone is in people with Multiple Sclerosis (MS)and moderate to severe MS-associated constipation.
- Trial name
- NCT01236534
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Multiple Sclerosis
Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients
Phase 4, single center, double-blind, placebo-controlled study. Fifty (50) patients with MacDonald criteria (2005) multiple sclerosis will undergo active motor training as per the NeuroGym protocol, consisting of 3 sessions of 1…
- Trial name
- NCT02146534
- Testing
- extended release fampridine
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Clinique Neuro-Outaouais
Central Neuropathic Pain, Multiple Sclerosis
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with multiple sclerosis.
- Trial name
- PRIME (NCT01324232)
- Testing
- AVP-923-45, AVP-923-30, AVP-923-20
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 209 people
- Sponsor
- Avanir Pharmaceuticals
Genetic and Inflammatory Polyneuropathies
Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France
To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France.
- Trial name
- POLYFRA (NCT07851844)
- Where
- 26 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Gait Disorders, Neurologic
TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Individuals with multiple sclerosis (MS) experience in impairments in mobility and cognition that increase the risk for accidental falls. More than 50% of individuals with MS experience injurious falls within a 6-month period.
- Conditions
- Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
- Trial name
- TRAIN-BW (NCT04091464)
- Testing
- Backward Walking Training, Forward Walking Training
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Wayne State University
Neuromyelitis Optica
Safety and Tolerability of Rituximab in Neuromyelitis Optica
The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO.
- Trial name
- NCT00501748
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.